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To the Editor:
Recently, Taylor and Holtby1 have pre-
sented a case of refractory hypotension in a
child with native mitral valve endocarditis
with cerebral complications in whom meth-
ylene blue (MB) was less effective than
previously described.2,3
We have been using MB to treat refrac-
tory vasoplegias since 1994, and our expe-
rience is corroborated by the specialized
medical literature. Most of our experience
involved adults who had hypotension dur-
ing cardiopulmonary bypass (CPB) or after
the operation, situation in which, like sep-
sis, nitric oxide plays a primordial role.4,5
In this milieu two prospective and random-
ized studies reached positive conclusions
about the efficacy of MB to treat6 or pre-
vent7 the vasoplegic syndrome in patients
having cardiac surgery with the aid of
CPB.
Recently, we operated on a drug-ad-
dicted young man with native aortic valve
endocarditis. The patient received a bileaf-
let valve prosthesis (St Jude Medical, Inc,
St Paul, Minn). A high dose of norepineph-
rine was necessary to maintain a reasonable
blood pressure during CPB. After weaning
from CPB he was hypotensive and had a
high cardiac output, low systemic vascular
resistance, and pulmonary edema. The ar-
terial oxygen saturation was below 80%,
even though he was being ventilated with
100% oxygen and positive end-expiratory
pressure. We started MB in a continuous
infusion in a way quite similar to that used
by Dr Taylor, followed by a bolus of 3
mg/kg (in 100 mL of 5% glucose in water)
twice a day. Even though the mean arterial
pressure did not increase, even with nor-
epinephrine, the cardiac output gradually
decreased, and the systemic vascular resis-
tance increased. In addition, the rapid res-
olution of lung edema resulting in higher
arterial oxygen saturation was astonishing.
Although Drs Taylor and Holtby seemed
disappointed with the effect of the MB on
blood pressure, we believe that their case
had an impressive evolution despite of its
severity. We disagree that “obvious clinical
scular Surgery ● January 2006improvement using MB was not evident in
this case,” since most of the pharmacologic
support to the circulation was necessary for
a short time. In our opinion, the contro-
versy about the use of MB to treat similar
cases arises when one uses MB merely as a
kind of “last-minute vasopressor.” MB
sometimes seems to work for this purpose
and sometimes it does not, perhaps due the
fact that, unlike many vasopressors, MB
does not act through a membrane receptor.
We believe the pivotal action of MB is not
exclusively the guanylyl cyclase blockage
resulting in a reduction in cyclic guanosine
monophosphate (cGMP). This blockage
also enhances the “crosstalk” between cy-
clic adenosine monophosphate (cAMP)
and cGMP pathways, which facilitates the
effect of the cAMP-dependent vasopres-
sors. Many clinical reports in the medical
literature, including sepsis treatment, sub-
stantiate that the guanilyl cyclase blockage
seems to improve the effect of the vaso-
pressors, shortening the length of pharma-
cologic cardiovascular support. Another
quite advantageous effect of MB is its ca-
pacity to reduce vascular permeability.8,9
Paulo Roberto B. Evora, MD, PhD
Alfredo José Rodrigues, MD, PhD
Division of Thoracic and Cardiovascular Surgery
Ribeirão Preto Faculty of Medicine
University of São Paulo
São Paulo, Brazil
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Reply to the Editor:
We thank Drs Evora and Rodrigues for their
interest in our case report and their com-
ments. The clinical improvement as de-
scribed in the series by Leyh and associates1
and the case reports by Grayling,2 Sparicio,3
and their colleagues, was not evident in our
case. Those authors described dramatic im-
provements in mean arterial pressure with
commencement of methylene blue (MB); our
patient experienced no such benefit. Norepi-
nephrine, epinephrine, and vasopressin re-
quirements persisted for at least the first 24
hours after the operation in our case. Her
treating intensivists believe that her postop-
erative course was not significantly shortened
by the use of MB. The dose used (2 mg/kg at
induction of anaesthesia, 2 mg/kg on initia-
tion of CPB, and an infusion of 1 mg/kg per
hour for a total of 4 hours) was based on the
description by Grayling and Deakin,2 which
is longer than that used by others.1,3
Nitric oxide vasodilation is implicated
in both sepsis and the refractory vasoplegia
associated with cardiopulmonary bypass
(CPB). The different outcomes in the stud-
ies of MB in the septic group and our
patient may be due to the different pathol-
ogy and underlying heterogeneity of septic
patients.4 A case report of dramatic im-
provement after MB in a patient with in-
fective endocarditis refutes this.2Evora and
doi:10.1016/j.jtcvs.2005.09.007Rodrigues describe the “random” efficacy
Tof MB when used as a “last minute vaso-
pressor.” The evidence for use of MB as
anything other than the “last minute vaso-
pressor” in such situations does not exist
for children. We, therefore, reiterate the
need for clinical trials to answer this ques-
tion.
Katherine Taylor, BMed( Hons ), BA, FANZCA
former Fellow in Paediatric Anaesthesia
The Hospital for Sick Children
Department of Anaesthesia
555 University Avenue
Toronto, Ontario M5G1X8, Canada
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Assumed oxygen consumption in the
determination of cardiac output in
children after cardiac surgery
To the Editor:
We read with interest the article by Fakler
and associates1 titled “Assumed oxygen
consumption frequently results in large er-
rors in the determination of cardiac out-
put.” However, we were surprised that our
previous article was not cited. We used
respiratory mass spectrometry to continu-
ously measure oxygen consumption (VO2)
and compared these direct measurements
with estimated VO2 values using 4 equa-
tions, including that of Lafarge and Miet-
tinen. We studied ventilated children with
congenital heart disease both during car-
diac catheterization and in the intensive
care unit early after cardiopulmonary by-
pass surgery.2 We showed an overestima-
tion of VO in children during cardiac cath-
doi:10.1016/j.jtcvs.2005.10.0132
eterization and an underestimation in the
he Journal of Thoracic and Cardiovascularpostoperative children, with all 4 equations
being particularly unreliable in the postop-
erative group.
As rightly pointed out by Fakler and
colleagues,1 use of assumed VO2 will result
in large errors in the calculation of hemo-
dynamic variables, such as cardiac output
and systemic and pulmonary vascular re-
sistance. This issue becomes particularly
important in patients during the early post-
operative period, when VO2 is not only
increased as a result of systemic inflamma-
tory response syndrome but is also highly
dependent on temperature,3 the use of ino-
tropes and vasoactive drugs,4 and ventila-
tory manipulation.5 Thus although the con-
clusions of Fakler and colleagues1 support
our previous observations regarding the use
of estimated VO2 during cardiac catheter-
ization, we believe our data suggest the
need for even greater caution in the more
highly dynamic hemodynamic milieu of
the postoperative cardiac intensive care
unit.
Jia Li, MD, PhD
Igor E. Konstantinov, MD, PhD
Glen S. Van Arsdell, MD
Andrew N. Redington, MD, FRCP
Cardiac Program
Hospital for Sick Children
Toronto, Ontario, Canada
References
1. Fakler U, Pauli C, Hennig M, Sebening W,
Hess J. Assumed oxygen consumption fre-
quently results in large errors in the determi-
nation of cardiac output. J Thorac Cardio-
vasc Surg. 2005;130:272-6.
2. Li J, Bush A, Schulze-Neick I, Penny DJ,
Redington AN, Shekerdemian LS. Measured
versus estimated oxygen consumption in ven-
tilated patients with congenital heart disease:
the validity of predictive equations. Crit Care
Med. 2003;31:1235-40.
3. Li J, Schulze-Neick I, Lincoln C, Shore D,
Scallan M, Bush A, et al. Oxygen consump-
tion after cardiopulmonary bypass surgery
in children: determinants and implications.
J Thorac Cardiovasc Surg. 2000;119:525-33.
4. Penny DJ, Sano T, Smolich JJ. Increased
systemic oxygen consumption offsets im-
proved oxygen delivery during dobutamine
infusion in newborn lambs. Intensive Care
Med. 2001;27:1518-25.
5. Li J, Hoskote A, Hickey C, Van Arsdell G,
Redington A, Adatia I. Hypercapnia im-
proves systemic oxygenation and decreases
oxygen consumption and blood lactate levels
in children after bidirectional cavopulmonary
shunt operation. Crit Care Med. 2005;33:
984-9.doi:10.1016/j.jtcvs.2005.08.014
Surgery ● Volume 131, Number 1 251
